By delivering an HIV vaccine candidate along with two adjuvants, researchers showed they could generate many more HIV-targeting B cells in mice.

Human volunteers will soon begin receiving an HIV vaccine that contains an adjuvant developed in Irvine’s lab, which helps to boost B cell responses to the vaccine.

Neural network identifies synergistic drug blends for treating viruses like SARS-CoV-2.

Using this computational system, researchers can identify viral protein sequences that could make better vaccine targets.

Differently shaped RNA molecules allow HIV to express different genes from the same RNA sequence.